Pricing
  1. JP-listed companies
  2. Carna Biosciences, Inc.
  3. Financials
  4. Cash and cash equivalents

Carna Biosciences, Inc. (4572)

Market cap
¥7.4B
P/E ratio
-3.5x
Karna Bioscience develops kinase inhibitor drugs and provides drug discovery support services to pharmaceutical companies and research institutions.
SummaryFinancialsDividendsHistorySegmentsOwnershipWorkforce
Period EndCash and cash equivalents (Million JPY)YoY (%)
Dec 31, 2025517-75.49%
Dec 31, 20242,108-27.02%
Dec 31, 20232,889-14.50%
Dec 31, 20223,379-11.49%
Dec 31, 20213,818-11.20%
Dec 31, 20204,299-12.53%
Dec 31, 20194,915+262.67%
Dec 31, 20181,355-26.99%
Dec 31, 20171,856-14.11%
Dec 31, 20162,161+33.00%
Dec 31, 20151,625+159.27%
Dec 31, 2014627

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat